Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

Characteristics of TBS-Extractable Hyperphosphorylated Tau Species: Aggregation Intermediates in rTg4510 Mouse Brain

(2018) Naruhiko Sahara et al.   JOURNAL OF ALZHEIMERS DISEASE

Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer

(2017) Doris Lambracht-Washington et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer

(2017) Doris Lambracht-Washington et al.   Alzheimers Research & Therapy

Tau passive immunization inhibits not only tau but also Aβ pathology

(2017) Chun-ling Dai et al.   Alzheimers Research & Therapy

Influence of immunoglobulin isotype on therapeutic antibody function

(2016) Stephen A. Beers et al.   BLOOD

A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies

(2016) Aurélien Lathuilière et al.   BRAIN

Halting of Caspase Activity Protects Tau from MC1-Conformational Change and Aggregation

(2016) Emma Mead et al.   JOURNAL OF ALZHEIMERS DISEASE

Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase

(2016) Haoling Qi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Failed Alzheimer’s trial does not kill leading theory of disease

(2016) Alison Abbott et al.   NATURE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Genomics of Alzheimer Disease

(2016) Roger N. Rosenberg et al.   JAMA Neurology

Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules

(2016) Hayk Davtyan et al.   Scientific Reports

DNA Aβ42 immunization generates a multivalent vaccine: Antibodies in plasma of active full-length DNA Aβ42 immunized mice show polyclonal Aβ42 peptide binding

(2015) Doris Lambracht-Washington et al.   Alzheimers & Dementia

Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy

(2015) Doris Lambracht-Washington et al.   JOURNAL OF NEUROIMMUNOLOGY

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

(2015) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Tau and neurodegenerative disease: the story so far

(2015) Khalid Iqbal et al.   Nature Reviews Neurology

A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients

(2015) Doris Lambracht-Washington et al.   NEUROBIOLOGY OF AGING

Tau Immunotherapy

(2015) Einar M. Sigurdsson   Neurodegenerative Diseases

Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice

(2014) Arne Ittner et al.   JOURNAL OF NEUROCHEMISTRY

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

(2014) Ken C. Walls et al.   NEUROSCIENCE LETTERS

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study

(2014) M Florencia Iulita et al.   Acta Neuropathologica Communications

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

(2013) Erin E. Congdon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

(2013) Jiaping Gu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice

(2013) Suhail Rasool et al.   JOURNAL OF NEUROCHEMISTRY

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

(2013) Clara Theunis et al.   PLoS One

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

(2012) Nadege Zommer et al.   Current Alzheimer Research

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease

(2012) Doris Lambracht-Washington et al.   JOURNAL OF NEUROIMMUNOLOGY

Neutralization of Soluble, Synaptotoxic Amyloid   Species by Antibodies Is Epitope Specific

(2012) W. Zago et al.   JOURNAL OF NEUROSCIENCE

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

(2012) Doris Lambracht-Washington et al.   Translational Neuroscience

DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

(2011) Doris Lambracht-Washington et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

Pathological roles of MAPK signaling pathways in human diseases

(2010) Eun Kyung Kim et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's disease

(2010) Bao-Xi Qu et al.   VACCINE

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

(2010) Carol Kilkenny et al.   PLOS BIOLOGY

DNA β-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model

(2009) Doris Lambracht-Washington   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

DNA vaccines: ready for prime time?

(2008) Michele A. Kutzler et al.   NATURE REVIEWS GENETICS

Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy

(2008) Nina Movsesyan et al.   PLoS One